Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
To read the full story
Related Article
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Pfizer’s Antibiotic Zavicefta Now Available in Japan
November 13, 2024
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- UCB’s Anti-Epileptic Drug Briviact Now Available in Japan
September 2, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- Fabhalta, Omjjara, Avigan Now Available in Japan
August 19, 2024
REGULATORY
- MHLW to Help Match Domestic Firms with Overseas Originators to Fight Drug Loss
May 12, 2025
- MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
- MHLW Official Explains Scope of Expanded Conditional Approval System at Diet
May 12, 2025
- Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
- MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…